PROCEDURAL STEPS TAKEN AFTER THE GRANTING OF THE MARKETING 
AUTHORISATION 
For procedures finalised after 15 October2003 please refer to module 8B. 
On  24  October  2001  the  EMEA,  following  submission  of  a  Type  I  variation  (EMEA/H/C/369/I/01), 
notified  a  change  in  the  name  of  the  manufacturer  of  the  active  substance  from  Bio  Science  Production 
Corp. to Cambrex Bio Science Inc. 
On 13 December 2001 the EMEA, further to the submission of a Type I variation (which followed a Type 
II  procedure:  EMEA/H/C/369/I/02),  notified  a  change  in  test  procedure  of  active  substance  and 
consequential changes in specifications of active substance and finished product, within the scope of item 
No 24 with consequential change no. 14 and 17 of Annex I to Commission Regulation (EC) No 542/95, as 
amended. 
On 17 January 2002 the EMEA, further to the submission of a Type I variation (which followed a Type II 
procedure: EMEA/H/C/369/I/03) notified a change in test procedure of active substance and consequential 
changes in specifications of active substance related to host cell proteins, within the scope of item No 24 
with consequential change no. 14 of Annex I to Commission Regulation (EC) No 542/95, as amended. 
On 17 January 2002 the EMEA, further to the submission of a Type I variation : (EMEA/H/C/369/I/04) 
concerning  a  minor  change  of  manufacturing  process  of  the  active  substance    within  the  scope  of  item  
No 12 of Annex I to Commission Regulation (EC) No 542/95, as amended. 
On  10  April  2002  the  European  Commission  issued  a  Decision  further  to  a  Marketing  Authorisation 
Holder  application  to  (EMEA/H/C/369/N/05)  to  introduce  a  number  of  minor  changes  to  aspects  of 
Labelling and Package Leaflet not connected to the Summary of Product Characteristics. 
On  24  May  2002  the  European  Commission  issued  a  Decision  on  a  Type  II  variation  application 
(EMEA/H/C/369/II/06) to update of Part II of the dossier. 
On  12  September  2002  the  European  Commission  issued  a  Decision  on  a  Type  II  variation 
(EMEA/H/C/369/II/07) to update the Part II of the dossier.  
On  10  September  2002,  the  European  Commission  issued  a  Decision  on  two  applications  for  Type  I 
variations  (EMEA/H/C/369/I/09  and  EMEA/H/C/369/I/10)  for  introduction  of  an  additional  4  vial 
multipack  presentation  and  an  additional  10  vial  multipack  presentation,  respectively,  to  the  originally 
approved single vial carton.  
On  3  October  2002  the  European  Commission  issued  a  Decision  on  the  Type  II  variation  procedure 
EMEA/H/C/369/II/08. This variation relates to updates of section 4.4, 4.8, 5.1 and 5.2 of the Summary of 
Product Characteristics (SPC) as a result of completion of the TKT014 study in female patients. 
On  21  October  2002  the  European  Commission  issued  a  Decision  on  a  Type  II  variation 
(EMEA/H/C/369/II/11) to update part II of the dossier. 
On  28  January  2003  the  European  Commission  issued  a  Decision  on  the  1st  Annual  Re-Assessment 
(EMEA/H/C/369/S/12) of the specific obligations and the benefit/risk ratio. The marketing authorisation 
for Replagal remained under exceptional circumstances. 
1/2 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
On  19  December  2002  the  EMEA,  following  submission  of  a  Type  I  variation  (EMEA/H/C/369/I/13) 
notified a change in the name of the manufacturer of the active substance from Cambrex Bio Science Inc. 
to Cambrex Bio Science Baltimore Inc.   
On  23  January  2003  the  EMEA,  further  to  the  submission  of  a  Type  I  variation,  (EMEA/H/C/369/I/14) 
notified a minor change of manufacturing process within the scope of item 12 to Commission Regulation 
(EC) No 542/95, as amended. 
On  17  February  2003  the  European  Commission  issued  a  Decision  on  the  Type  I  variation 
EMEA/H/C/369/I/15, regarding an extension of shelf-life as foreseen at time of authorisation. 
On  19  March  2003  the  EMEA,  further  to  submission  of  a  Type  I  variation  (which  followed  a  Type  II 
procedure: EMEA/H/C/369/I/16), notified a change in the manufacturing process for the finished product. 
This  variation  falls  within  the  scope  of  item  No  16  of  Annex  I  to  Commission  Regulation  (EC)  
No 542/95, as amended. 
On  22  July  2003 
issued  a  Decision  on  a  Type  II  variation 
(EMEA/H/C/369/II/17)  relating  to  the  introduction  of  a  new  manufacturing  facility  for  the  active 
substance and to implement several process improvements.  
the  European  Commission 
the  European  Commission 
On  3  October  2003 
issued  a  Decision  on  a  Type  II  variation 
(EMEA/H/C/369/II/18) regarding amendments to sections 4.4 and 4.8 of the SPC, and to include changes 
resulting  from  recoding  of  the  clinical  trials  safety  database  from  the  WHOART  98.3  dictionary  to 
MedDRA 5.1. 
2/2 
EMEA 2004 
 
 
 
 
 
 
 
 
 
 
